Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Cash Equivalents
Adaptimmune Therapeutics PLC
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Cash Equivalents
$140.7m
|
CAGR 3-Years
63%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash Equivalents
£442.6m
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Adaptimmune Therapeutics PLC's Cash Equivalents?
Cash Equivalents
140.7m
USD
Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Cash Equivalents amounts to 140.7m USD.
What is Adaptimmune Therapeutics PLC's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
23%
Over the last year, the Cash Equivalents growth was 17%. The average annual Cash Equivalents growth rates for Adaptimmune Therapeutics PLC have been 63% over the past three years , 23% over the past five years .